Histogen Funding: How Much Did They Raise & Key Investors

How Much Did Histogen Raise?
Funding & Key Investors

Histogen, a clinical-stage therapeutics innovator, has successfully secured a significant capital injection, bringing its cumulative financial backing to $37.3M. This latest major strategic investment of $5M underscores the market confidence in the company's proprietary technology platform. By leveraging hypoxia-induced multipotent cells, Histogen continues to advance its mission of developing first-in-class restorative therapeutics designed to ignite the body's natural repair mechanisms. This infusion of capital serves as a critical milestone in the company's trajectory, providing the necessary resources to accelerate its clinical development pipeline and solidify its position within the competitive regenerative medicine landscape.

The funding history, which spans from its initial private equity rounds in 2007 to the most recent share placement in 2022, reflects a sustained commitment to long-term growth. As the company transitions through various stages of development, this recent financing round acts as a catalyst for scaling its manufacturing capabilities and expanding its therapeutic reach across diverse indications, including spinal disk repair and soft tissue regeneration.

What is Histogen?

Histogen

Manufacturing

Pharmaceuticals

Business Services

Histogen Inc. operates at the intersection of biotechnology and regenerative medicine, focusing on the development of restorative therapeutics that utilize cell-conditioned media and extracellular matrix materials. The company's core innovation lies in its proprietary manufacturing process, which produces targeted solutions for complex medical needs. By focusing on hypoxia-induced multipotent cells, Histogen addresses critical gaps in current treatment protocols for joint cartilage regeneration, tendon repair, and ligament restoration. Its market position is defined by its ability to translate complex biological functions into reproducible, clinical-grade therapeutic products, positioning it as a key player in the future of tissue engineering and restorative healthcare.

How much funding has Histogen raised?

Histogen has raised a total of $37.3M across 6 funding rounds:

2007

Private Equity

$9.5M

2016

Private Equity

$6M

2020

Debt

$350K

Share Placement

$10M

2021

Stock Offering

$6.5M

2022

Share Placement

$5M

Private Equity (2007): $9.5M, investors not publicly disclosed

Private Equity (2016): $6M led by Huapont Life Sciences Co.

Debt (2020): $350K supported by PPP

Share Placement (2020): $10M, investors not publicly disclosed

Stock Issuance/Offering (2021): $6.5M, investors not publicly disclosed

Share Placement (2022): $5M, investors not publicly disclosed

Key Investors in Histogen

Huapont Life Sciences Co.

Huapont Life Sciences is a prominent pharmaceutical manufacturer listed on the Shenzhen Stock Exchange, specializing in dermatological, respiratory, and anti-tumor medications with a robust global API export footprint.

Undisclosed Investor

Undisclosed investor participating in the funding round.

PPP

Public-Private Partnership

What's next for Histogen?

With the successful closure of this recent funding round, Histogen is well-positioned to advance its clinical-stage assets through rigorous regulatory pathways. The strategic allocation of these funds will likely prioritize the expansion of its manufacturing infrastructure and the acceleration of ongoing clinical trials. As the company continues to refine its restorative technology, the focus will shift toward achieving key clinical endpoints that validate the efficacy of its extracellular matrix materials. Investors and industry stakeholders will be closely monitoring the company's progress as it seeks to translate its innovative research into commercialized therapeutic solutions, potentially disrupting traditional treatment paradigms in orthopedics and soft tissue repair.

See full Histogen company page

See More Financial Insights